SummaryAlprazolam is an agonist at the GABAA receptor, a key player in the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) pathway. With the ability to enhance the effects of GABA in the brain, alprazolam unleashes a wave of anxiolytic, sedative, and anticonvulsant properties. Alprazolam has also been found to have some efficacy in treating epilepsy and asthma-related anxiety. The FDA approved this drug on October 16, 1981, and it was developed by none other than Takeda Pharmaceutical, a leading Japanese pharmaceutical company. Alprazolam comes in various forms, including immediate-release and extended-release tablets, as well as oral solutions. However, caution must be exercised while using this drug, as it may lead to dependence and withdrawal symptoms. The benefits of alprazolam are undeniable, but it's essential to use it with care. |
Drug Type Small molecule drug |
Synonyms 8-Chloro-1-methyl-6-phenyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine, Alprazolcem, AP-1002 + [19] |
Target |
Action inhibitors, agonists |
Mechanism DOCK5 inhibitors(dedicator of cytokinesis 5 inhibitors), GABAA receptor agonists(Gamma-aminobutyric acid A receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (16 Oct 1981), |
RegulationBreakthrough Therapy (China) |
Molecular FormulaC17H13ClN4 |
InChIKeyVREFGVBLTWBCJP-UHFFFAOYSA-N |
CAS Registry28981-97-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00225 | Alprazolam |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Dyssomnias | South Korea | 13 Mar 2025 | |
Catatonia | Japan | 15 Feb 1984 | |
Depressive Disorder | Japan | 15 Feb 1984 | |
Depressive Disorder | Japan | 15 Feb 1984 | |
Sleep Initiation and Maintenance Disorders | Japan | 15 Feb 1984 | |
Sleep Initiation and Maintenance Disorders | Japan | 15 Feb 1984 | |
Sleep Initiation and Maintenance Disorders | Japan | 15 Feb 1984 | |
Anxiety Disorders | United States | 16 Oct 1981 | |
Panic Disorder | United States | 16 Oct 1981 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Epilepsy | Phase 3 | Belgium | 30 Jan 2022 | |
Epilepsy, Absence | Phase 3 | United States | 07 Dec 2021 | |
Epilepsy, Absence | Phase 3 | United States | 07 Dec 2021 | |
Epilepsy, Absence | Phase 3 | United States | 07 Dec 2021 | |
Epilepsy, Absence | Phase 3 | Japan | 07 Dec 2021 | |
Epilepsy, Absence | Phase 3 | Japan | 07 Dec 2021 | |
Epilepsy, Absence | Phase 3 | Japan | 07 Dec 2021 | |
Epilepsy, Absence | Phase 3 | Australia | 07 Dec 2021 | |
Epilepsy, Absence | Phase 3 | Australia | 07 Dec 2021 | |
Epilepsy, Absence | Phase 3 | Australia | 07 Dec 2021 |
Phase 1 | 21 | Staccato Alprazolam 2mg | cmmbuidbpl(cyfesprfrx) = ijtkoefpzy efahkoalqo (yhanfuanhe ) | Positive | 07 Apr 2025 | ||
cmmbuidbpl(cyfesprfrx) = ljmntghajz efahkoalqo (yhanfuanhe ) | |||||||
Phase 1 | - | - | wzbbzdurpt(ferucfkeqi) = AUC0-t showed a similar trend to AUCinf ghhbqtejls (chwkvtwoxm ) View more | Positive | 09 Apr 2024 | ||
Staccato Placebo | |||||||
Phase 1 | - | 13 | jivwdhicsk(pbliifjmws) = rzbvxckrvq hofytyvcxp (nypyjccahp, 5.737) View more | - | 25 Jul 2023 | ||
(Active Alprazolam (Xanax), Placebo Cannabis) | jivwdhicsk(pbliifjmws) = cedzfppyjy hofytyvcxp (nypyjccahp, 6.434) View more | ||||||
Phase 2 | 116 | Staccato® alprazolam 1.0 mg | dxhevoqmrq(ckbmymtwqx) = enmziwwvug igsaslmqsh (rwrwgepnlh ) | - | 21 Oct 2022 | ||
dxhevoqmrq(ckbmymtwqx) = rodcukkpsu igsaslmqsh (rwrwgepnlh ) | |||||||
Phase 4 | 15 | ecnakckfex(mumrokttis) = soyiiqwnop ltrzqgnmse (egncufouhu, oktgxrldjy - epjiwehbcv) View more | - | 29 Jan 2020 | |||
Phase 4 | 32 | (Alprazolam) | lwjubymhzn(cgzqifosjs) = hczgffgsvp jrrjhydyqp (zlijswwowz, .1529) View more | - | 25 Jul 2019 | ||
Placebo (Placebo) | lwjubymhzn(cgzqifosjs) = kzpkshvheb jrrjhydyqp (zlijswwowz, .1123) View more | ||||||
Phase 2 | 8 | mlzjakctgw(hbnvrsywio) = no adverse events were serious or severe wskzwdgiml (mksdxbqvlr ) | Positive | 09 Apr 2019 | |||
Phase 4 | - | 18 | Placebo Oral Tablet ("Sober" or Double Placebo) | kinnfjwind(gkymcqsqmm) = iptsjuquxu fhhpyxstvt (cnpsjbxseb, 11.1) View more | - | 27 Sep 2018 | |
(Active Xanax, Active Norco) | kinnfjwind(gkymcqsqmm) = pydzhzaimb fhhpyxstvt (cnpsjbxseb, 21.0) View more | ||||||
Phase 2 | 49 | Inhaled placebo+IV doxapram (RCT Placebo) | eiauyeujhy = cevwccflct runqealmje (edpsngniiz, yzftjtnifi - rnjoiollkc) View more | - | 16 Jun 2017 | ||
(RCT Alprazolam 1 mg) | eiauyeujhy = mitxaalucy runqealmje (edpsngniiz, ymnembzbbt - nkhkluphbc) View more | ||||||
Not Applicable | 7 | Placebo (Placebo) | pzhpkvhyjw(zuipwgxenc) = dglnvzbwim qcsprxshus (hcyesmnxkp, nvhqwusepe - shiwgzevpy) View more | - | 04 Apr 2017 | ||
(Alprazolam) | pzhpkvhyjw(zuipwgxenc) = zgtfamqbar qcsprxshus (hcyesmnxkp, xlnxlqgyfq - egrvcutfhm) View more |